№ lp_1_2_48513
File format: docx
Character count: 23745
File size: 190 KB
Official clinical practice guidance outlining standards and safety considerations for the administration of intravenous immunoglobulin in Australian healthcare settings, including product-specific information and national regulatory context.
Date:
March 2023
Country:
Australia
Subject:
Intravenous immunoglobulin administration
Document type:
Clinical practice guidance
Healthcare setting:
Hospital and health services
Target audience:
Healthcare professionals involved in IVIg prescribing and administration
Regulatory context:
BloodSTAR authorization and national IVIg criteria
Products referenced:
Privigen®, Kiovig®, Flebogamma®, Gammunex®, Octagam®, Intragam®10
Effective period:
From April 2023
Clinical scope:
Indications, precautions, preparation, infusion, storage, and adverse effects
Source type:
Official guidance
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Version:
V3.0
Author:
Dr Julia Sikorska, Consultant Haematologist, STSTN Clinical Guidelines Group
Note:
2019
Executive/Divisional sponsor:
Via Hospital Transfusion Committee
Applies to:
All staff involved in the care of patients with Sickle Cell Disease
Date issued:
V3.0 February 2020
Review date:
February 2023
Approval person/Committee:
Hospital Transfusion Committee
Date:
March 2020
Year:
2020
Region / city:
St George’s, UK
Topic:
Hyperhaemolysis management in Haemoglobinopathies
Document type:
Clinical guidelines
Organization / institution:
St George’s University Hospitals NHS
Target audience:
Healthcare staff involved in the care of Sickle Cell Disease patients
Effective period:
February 2020–February 2023
Approval date:
March 2020
Year:
2023
Country:
Australia
Document type:
Clinical guidance
Organization:
Australian Government Department of Health / Blood Service
Target audience:
Healthcare professionals administering IVIg
Scope:
IVIg administration, safety, and monitoring
Effective from:
April 2023
References:
Criteria for the clinical use of intravenous immunoglobulin in Australia, 3rd edition, October 2018; Product information sheets of Privigen®AU, Kiovig®, Flebogamma®, Gammunex®, Octagam®
Appendices:
Product comparison, infusion rate guides
Program:
Medicare IVIG Demonstration
Administering Agency:
Centers for Medicare & Medicaid Services (CMS)
Country:
United States
Legal Basis:
Medicare IVIG Access and Strengthening Medicare and Repaying Taxpayers Act of 2012
Extended Under:
Disaster Tax Relief and Airport and Airway Extension Act of 2017
Further Extension:
Consolidated Appropriations Act, 2021
OMB Control Number:
0938-1246
CMS Form Number:
CMS-10518
Subject:
Application for beneficiary participation in the IVIG Demonstration
Target Population:
Medicare Part B beneficiaries with primary immune deficiency disease (PIDD)
Enrollment Cap:
6,500 beneficiaries (originally 4,000)
Funding Limit:
$45 million including administrative and evaluation costs
Coverage Scope:
Bundled payment for medically necessary supplies and services for in-home IVIG administration
Application Requirement:
Mandatory signed application by beneficiary and provider
Submission Methods:
Mail or fax
Languages Available:
English and Spanish
Period of Demonstration:
Through December 31, 2023 or until statutory limits are met
Participation Status:
Voluntary; may be terminated by beneficiary at any time
Version:
V3.0
Author:
Dr Julia Sikorska, Consultant Haematologist, STSTN Clinical Guidelines Group
Note:
2019
Executive/Divisional sponsor:
Via Hospital Transfusion Committee
Applies to:
All staff involved in the care of patients with Sickle Cell Disease
Date issued:
V3.0 February 2020
Review date:
February 2023
Approval person/Committee:
Hospital Transfusion Committee
Date:
March 2020
Year:
2020
Region / city:
St George’s, UK
Topic:
Hyperhaemolysis management in Haemoglobinopathies
Document type:
Clinical guidelines
Organization / institution:
St George’s University Hospitals NHS
Target audience:
Healthcare staff involved in the care of Sickle Cell Disease patients
Effective period:
February 2020–February 2023
Approval date:
March 2020
Year:
2024
Region / city:
Canberra
Topic:
Immunology, Blood Products
Document Type:
Procedure
Organization / Institution:
Canberra Health Services
Author:
Not specified
Target Audience:
Medical Officers, Nurses, Midwives, Students under direct supervision
Period of validity:
Not specified
Approval Date:
Not specified
Date of Changes:
Not specified
Year:
2026
Region / City:
Australia
Theme:
Medical Travel, Blood Products, SCIg
Document Type:
Official Guidelines
Organization / Institution:
Australian Red Cross Lifeblood, National Blood Authority, Victorian Government Department of Health
Author:
Victorian Government, Department of Health
Target Audience:
Medical professionals, Patients requiring SCIg
Period of Validity:
Not specified
Date of Approval:
January 2026
Date of Last Update:
January 2026
Year:
2023
Country:
Australia
Document type:
Clinical guidance
Organization:
Australian Government Department of Health / Blood Service
Target audience:
Healthcare professionals administering IVIg
Scope:
IVIg administration, safety, and monitoring
Effective from:
April 2023
References:
Criteria for the clinical use of intravenous immunoglobulin in Australia, 3rd edition, October 2018; Product information sheets of Privigen®AU, Kiovig®, Flebogamma®, Gammunex®, Octagam®
Appendices:
Product comparison, infusion rate guides
Year:
Not specified
Region / City:
Not specified
Subject:
Tetanus prevention, immunization, post-exposure prophylaxis
Document Type:
Medical guideline
Organization / Institution:
Not specified
Author:
Not specified
Target Audience:
Healthcare professionals, medical practitioners
Period of validity:
Not specified
Approval Date:
Not specified
Date of Changes:
Not specified
Year:
2004-2016
Region / City:
Queensland, Australia
Topic:
Public health, immunoglobulin use
Document Type:
Research paper
Organization / Institution:
Griffith University, The Prince Charles Hospital, National Blood Authority
Author:
Megan K Young, Allan W Cripps, Graeme R Nimmo
Target Audience:
Public health professionals, researchers
Effective Period:
2004-2016
Approval Date:
N/A
Date of Revisions:
N/A
Year:
2026
Region / City:
United Kingdom
Subject:
Perinatal Hepatitis B Prevention
Document Type:
Medical Request Form
Institution:
NHS
Author:
Healthcare Practitioner
Target Audience:
Hospital staff and pharmacists
Period of Use:
Antenatal and postnatal period
Date of Issue:
2026
Instructions Included:
Yes
Emergency Procedures:
Yes
Vaccine Administration Guidelines:
Yes
Maternal Antiviral Treatment Recorded:
Yes
Infant Delivery and Health Data:
Yes
Form Submission Method:
Email
Year:
2026
Region / City:
United Kingdom
Topic:
Veterinary Immunology / Equine Asthma
Document Type:
Research Article
Institution:
University Veterinary Research Center
Authors:
[Not specified in document]
Target Audience:
Veterinary researchers, equine clinicians
Study Period:
Not explicitly stated
Sample Size:
12 horses (6 sEA-affected, 6 healthy controls)
Methodology:
Protein microarray-based IgE profiling
Key Findings:
Identification of novel allergens associated with severe equine asthma, reproducibility and specificity of microarray validated
Year:
2026
Region / City:
Western Australia
Subject:
Public Health, Rabies Immunoglobulin Supply
Document Type:
Guidelines, Information for Doctors
Organization:
Government of Western Australia, Department of Health
Author:
Department of Health, Public Health and Clinical Services, Communicable Disease Control Directorate
Target Audience:
Public Health Units, On-call Doctors
Period of Validity:
Ongoing
Approval Date:
Not specified
Amendment Date:
Not specified
Year:
2023
Region / City:
Canberra, Australia
Topic:
Paediatric intravenous extravasation management
Document Type:
Guideline
Organization:
Canberra Health Services
Author:
Expert clinical reference groups
Target Audience:
Clinicians in paediatric care
Period of validity:
Ongoing
Approval Date:
7 December 2023
Amendment Date:
26 August 2024
Organisation:
Canberra Health Services
Region:
Canberra, Australian Capital Territory, Australia
Healthcare setting:
Hospital in the Home
Clinical area:
Cardiology
Condition:
Congestive cardiac failure
Patient population:
Adults
Type of document:
Clinical procedure
Route of administration:
Intravenous
Treatment:
Furosemide
Admission criteria:
Defined clinical and general eligibility requirements
Source type:
Institutional clinical guideline
Version:
V3.0
Author:
Dr Julia Sikorska, Consultant Haematologist, STSTN Clinical Guidelines Group
Note:
2019
Executive/Divisional sponsor:
Via Hospital Transfusion Committee
Applies to:
All staff involved in the care of patients with Sickle Cell Disease
Date issued:
V3.0 February 2020
Review date:
February 2023
Approval person/Committee:
Hospital Transfusion Committee
Date:
March 2020
Year:
2020
Region / city:
St George’s, UK
Topic:
Hyperhaemolysis management in Haemoglobinopathies
Document type:
Clinical guidelines
Organization / institution:
St George’s University Hospitals NHS
Target audience:
Healthcare staff involved in the care of Sickle Cell Disease patients
Effective period:
February 2020–February 2023
Approval date:
March 2020
Year:
2022
Region / city:
New South Wales, Australia
Theme:
Medical procedure / MRI contrast agent administration
Document Type:
Standing order
Organization / institution:
New South Wales Health
Author:
NSW Health
Target audience:
Medical professionals, particularly those involved in MRI procedures
Period of validity:
Until approval by hospital/district DTC
Approval date:
Not specified
Date of changes:
Not specified
Note:
Contextual description
Year:
[effective date]
Region / City:
[Facility Location]
Topic:
Intravenous to Oral Antibiotic Conversion
Document Type:
Policy
Organ / Institution:
[Facility Name]
Author:
[Approving individual or committee]
Target Audience:
Clinical staff, healthcare providers
Period of Effectiveness:
[Effective date]
Approval Date:
[Approval Date]
Date of Changes:
[Date of Changes]
Year:
2026
Region / city:
Canberra
Topic:
Clinical Procedures, Healthcare, Intravenous Access
Document Type:
Procedure
Organization / institution:
Canberra Health Services
Author:
Not specified
Target audience:
Healthcare professionals at Canberra Health Services
Effective period:
Ongoing
Approval date:
Not specified
Revision date:
Not specified
Document type:
Medication standing order
Clinical area:
Medical imaging and diagnostic radiology
Patient population:
Adults aged 16 years and over
Medication:
Iohexol iodinated contrast media
Route of administration:
Intravenous injection
Indication:
Contrast-enhanced CT imaging studies
Applicable organisations:
NSW public health organisation imaging departments
Exclusions:
Paediatric patients under 16 years of age
Regulatory framework:
NSW State Form SMR060.160 and PD2013_043 Medication Handling in NSW Public Health Facilities
Authorised personnel:
Registered nurses and accredited medical radiation scientists meeting AHPRA and HETI requirements
Contraindications:
Known hypersensitivity to iodinated contrast media; high-risk renal impairment without medical officer approval
Risk considerations:
Contrast-induced acute kidney injury and hypersensitivity reactions
Guideline references:
RANZCR Iodinated Contrast Media Guideline 2018; ACR Manual on Contrast Media 2018
Approval requirements:
Changes require approval by a radiologist or medical officer
Review requirement:
Annual review for currency